Abstract
Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Current Pharmaceutical Design
Title: New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways
Volume: 15 Issue: 14
Author(s): Akira Nishida, Tsuyoshi Miyaoka, Takuji Inagaki and Jun Horiguchi
Affiliation:
Keywords: Depressive disorder, antidepressant, cytokine, interleukin, interferon, sickness behavior
Abstract: Monoamine oxidase inhibitor and tricyclic antidepressants have been serendipitously used for the treatment of depression for more than half a century and subsequently found to promote monoaminergic signals in the brain. Antidepressant dugs are still clinically used and industrially designed on the basis of the monoaminergic theory. Recent developments regarding selective monoaminergic uptake inhibitors can further improve the safe and rational treatment for patients with depression. However, monoamine-based antidepressants may cause unfavorable and incomplete remission of a considerable number of patients with depression; therefore, development of new antidepressant drugs based on other mechanisms is required. Meanwhile, there has been an impressive accumulation of knowledge about cytokines that might contribute to the understanding of the pathophysiology of depression. Therefore, this review focuses on the association between depressive disorder and cytokines and discusses the strategies for developing new cytokine-based antidepressant drugs.
Export Options
About this article
Cite this article as:
Nishida Akira, Miyaoka Tsuyoshi, Inagaki Takuji and Horiguchi Jun, New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways, Current Pharmaceutical Design 2009; 15 (14) . https://dx.doi.org/10.2174/138161209788168065
DOI https://dx.doi.org/10.2174/138161209788168065 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Platelet/Lymphocyte Serotonin Transporter in Depression and Beyond
Current Drug Targets Patent Selections
Recent Patents on Food, Nutrition & Agriculture Block Copolymers for Drug Delivery Nano Systems (DDnSs)
Current Medicinal Chemistry Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Gene-Nutrient Interactions in One-Carbon Metabolism
Current Drug Metabolism Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals
Current Pharmaceutical Design Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design Modifying TNF alpha for Therapeutic Use A Perspective on the TNF Receptor System
Mini-Reviews in Medicinal Chemistry Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews Regulation of Vascular Genes by Glucose
Current Pharmaceutical Design New Developments in Peroxidation of Polyunsaturated Fatty Acids
Letters in Organic Chemistry Impacts of Particulate Air Pollution on Asthma: Current Understanding and Future Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery Identification of Differentially Expressed Hematopoiesis-associated Genes in Term Low Birth Weight Newborns by Systems Genomics Approach
Current Genomics Patent Selections
Recent Patents on Drug Delivery & Formulation Expression and Purification of Tag-removed Human IL37 by Digestion on Beads in Escherichia coli
Protein & Peptide Letters Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Temporal and Spatial Distribution of Macrophage Subpopulations During Arteriogenesis
Current Vascular Pharmacology Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety